ST. PETERSBURG, Fla., Sept. 9, 2011 /PRNewswire/ -- The Advanced Wound Management division of Smith & Nephew (LSE: SN; NYSE: SNN) today announced results from 11 studies on a range of products and therapies from their ALLEVYN*, ACTICOAT*, IODOSORB* and RENASYS* wound care portfolio. The data demonstrate advanced healing strategies and the efficacy of the company's specialized advanced wound care products. Results of the studies are being presented at the Clinical Symposium on Advances in Skin & Wound Care (CSASWC), a national convention for wound care professionals.
The results of the IODOSORB trial will be shared as a podium presentation. This was a prospective, non-comparative, multicenter study investigating the effect of IODOSORB on bioburden load and other wound characteristics in diabetic foot ulcers. Elevated bacterial burden has been cited as a contributing factor in the delayed healing of these types of ulcers. The study showed significant evidence (p=0.008) of reduction in the clinical signs of infection when IODOSORB was used.
"The study results showed that when IODOSORB was used on diabetic foot ulcers, significant reductions in wound area, levels of exudates and pain were seen in patients, as well as an improvement in wound appearance," said Dr. John Lantis II, Chief of Division, Endovascular-Vascular Surgery, Director of Clinical Research, Department of Surgery, St. Lukes-Roosevelt Hospital Center, New York and author of the research. "This is encouraging news for patients, as foot ulcers occur in nearly 15 percent of all patients with diabetes."
In addition to the new clinical data being presented at CSASWC, Smith & Nephew will also introduce the new ALLEVYN Gentle B